Firsekibart for treating systemic sclerosis (scleroderma)
Treatments studied
Part of Skin clinical trials.
This trial tests a new medication called Firsekibart for people with systemic sclerosis (scleroderma). The goal is to see if it helps reduce skin thickening and other symptoms, and it might be an option if standard treatments haven't worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with systemic sclerosis (scleroderma) by a doctor.
- Your disease started within the last 5 years (not counting Raynaud's).
- You have noticeable skin thickening or tightness (measured as moderate or more).
- You are not currently pregnant or breastfeeding.
- You have not used certain biologic medications or stem cell therapy in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a new medicine called Firsekibart for people who have frequent gout attacks. It aims to see if the medicine can reduce the chance of another attack over 24 weeks.
This trial tests a new drug called firsekibart against an existing drug, anakinra, for people with active adult-onset Still's disease. It aims to see if firsekibart is more effective in controlling symptoms like fever, joint pain, and rash.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
Hear when a new Systemic Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.